Stockholm3 在多种族队列中检测前列腺癌(SEPTA):一项前瞻性多中心试验
SEPTA 是一项观察性前瞻性多中心试验,纳入 2129 例疑似前列腺癌并接受活检的男性,评估 Stockholm3 与 PSA 对 ISUP 分级≥2 临床显著前列腺癌的检测效能。Stockholm3 相对 PSA≥4 ng/mL 的灵敏度非劣(相对灵敏度 0.95,95%CI 0.92–0.99),特异度接近三倍(相对特异度 2.91,95%CI 2.63–3.22)。
要点
- Stockholm3 对临床显著前列腺癌的灵敏度非劣于 PSA≥4 ng/mL,相对灵敏度 0.95(95%CI 0.92–0.99)。
- Stockholm3 特异度接近 PSA 的三倍,相对特异度 2.91(95%CI 2.63–3.22)。
- Stockholm3 总体可减少 45% 良性及 ISUP 1 级活检,各种族亚组间减少 42%–52%。
核心结论
- 在高度多样的人群中,Stockholm3 显著减少不必要的前列腺活检,同时检测临床显著前列腺癌的灵敏度与 PSA 相似。
研究设计与样本
- 观察性前瞻性多中心(17 个中心)临床试验(2019–2023 年),并补充前瞻性招募的参与者(2008–2020 年),均在泌尿外科门诊环境下纳入疑似前列腺癌并接受前列腺活检的男性。
- 共纳入 2129 例接受活检的参与者:亚裔 16%(350 例)、黑人或其他非洲裔美国人(黑人)24%(505 例)、西班牙裔或拉丁裔及白人(西班牙裔)14%(305 例)、非西班牙裔或非拉丁裔及白人(白人)46%(969 例)。
- 活检前采集样本检测 Stockholm3 风险评分,参数包括前列腺特异性抗原(PSA)、游离 PSA、KLK2、GDF15、PSP94、胚系风险(单核苷酸多态性)、年龄、家族史和既往阴性活检。
- 主要终点为国际泌尿病理学会(ISUP)分级≥2 癌症(临床显著前列腺癌,csPC)的检出;两个主要目标为(1)证明 Stockholm3 相对 PSA 检测 csPC 的灵敏度非劣(相对灵敏度,非劣效界值 0.8,95%CI 下限)和(2)证明通过减少良性结果或低级别癌症的活检而具有更优特异度(相对特异度)。
主要发现
- Stockholm3 相对 PSA≥4 ng/mL 的灵敏度非劣(相对灵敏度 0.95,95%CI 0.92–0.99),特异度接近三倍(相对特异度 2.91,95%CI 2.63–3.22)。
- 结果在种族和族裔亚组中一致:灵敏度非劣(0.91–0.98),特异度更优(2.51–4.70)。
- 与 PSA 相比,Stockholm3 总体可减少 45% 的良性及 ISUP 1 级活检,各种族和族裔亚组间减少 42%–52%。
关键数值与推荐
- Stockholm3 相对 PSA≥4 ng/mL 检测 csPC 的相对灵敏度为 0.95(95%CI 0.92–0.99),满足非劣效界值 0.8。
- Stockholm3 相对 PSA 的相对特异度为 2.91(95%CI 2.63–3.22)。
- 种族和族裔亚组的相对灵敏度为 0.91–0.98,相对特异度为 2.51–4.70。
- Stockholm3 总体减少良性及 ISUP 1 级活检 45%,各种族和族裔亚组减少 42%–52%。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Asian, Black, and Hispanic men are underrepresented in prostate cancer (PCa) clinical trials. Few novel prostate cancer biomarkers have been validated in diverse cohorts. We aimed to determine if Stockholm3 can improve prostate cancer detection in a diverse cohort. METHODS: An observational prospective multicentered (17 sites) clinical trial (2019-2023), supplemented by prospectively recruited participants (2008-2020) in a urology clinic setting included men with suspicion of PCa and underwent prostate biopsy. Before biopsy, sample was collected for measurement of the Stockholm3 risk score. Parameters include prostate-specific antigen (PSA), free PSA, KLK2, GDF15, PSP94, germline risk (single-nucleotide polymorphisms), age, family history, and previous negative biopsy. The primary endpoint was detection of International Society of Urological Pathology (ISUP) Grade ≥2 cancer (clinically significant PCa, csPC). The two primary aims were to (1) demonstrate noninferior sensitivity (0.8 lower bound 95% CI noninferiority margin) in detecting csPC using Stockholm3 compared with PSA (relative sensitivity) and (2) demonstrate superior specificity by reducing biopsies with benign results or low-grade cancers (relative specificity). RESULTS: A total of 2,129 biopsied participants were included: Asian (16%, 350), Black or African American (Black; 24%, 505), Hispanic or Latino and White (Hispanic; 14%, 305), and non-Hispanic or non-Latino and White (White; 46%, 969). Overall, Stockholm3 showed noninferior sensitivity compared with PSA ≥4 ng/mL (relative sensitivity: 0.95 [95% CI, 0.92 to 0.99]) and nearly three times higher specificity (relative specificity: 2.91 [95% CI, 2.63 to 3.22]). Results were consistent across racial and ethnic subgroups: noninferior sensitivity (0.91-0.98) and superior specificity (2.51-4.70). Compared with PSA, Stockholm3 could reduce benign and ISUP 1 biopsies by 45% overall and between 42% and 52% across racial and ethnic subgroups. CONCLUSION: In a substantially diverse population, Stockholm3 significantly reduces unnecessary prostate biopsies while maintaining a similar sensitivity to PSA in detecting csPC.
引用
- Vigneswaran HT, Eklund M, Discacciati A, et al. Stockholm3 in a Multiethnic Cohort for Prostate Cancer Detection (SEPTA): A Prospective Multicentered Trial. J Clin Oncol. 2024. PMID: 39038251. doi:10.1200/JCO.24.00152
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。